Blog

Bishal Gyawali: Our major publications from last 2 months

Bishal Gyawali/scri.queensu.ca

Feb 3, 2025, 08:17

Bishal Gyawali: Our major publications from last 2 months

Bishal Gyawali, Associate Professor at Queen’s University, Kingston, posted on X:

“These last 2 months have been our milestone months. We have published some- in my opinion- really important pieces. Since there are many new followers, I want to summarize here our major publications from last 2 months that I hope everyone reads.

1. How much did public funds contribute to the development of Xtandi? And how much are we paying for this drug now? The need for increased transparency of public funds in development of new drugs is important so that the public don’t pay twice.

“Government Funding for the Development of Enzalutamide”

2. How to define and measure financial toxicity correctly in LMICs? The first comprehensive review of measurement tools in FT in LMICs context.

“Defining and Measuring Financial Toxicity in Low- and Middle-Income Countries”

3. Our critique of why the control arm in the ARANOTE trial was clearly beneath the standard of care.

“Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial”

4. Update on global access and availability of anticancer drugs as a part of ESMO study.

“ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update”

5. Showing how perceived -inferiority censoring can be informative and explain so-assumed “different” outcomes for drugs of same class in same cancer. Also Why extra attention should be paid to PFS-only drugs.

“Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring”

6. We provide objective evidence-based rebuttal against all arguments claiming “OS can no longer be the primary endpoint of cancer drug trials” in this Medscape column.

7. 2 more videos in the Medscape Skills Lab series on how to read a cancer drug clinical trial correctly.

PS: One of the most important articles will be published in the February edition of The Lancet Oncology. Stay tuned.”